Nordic Life Science 1
xxx xxx CEO of Alligator Bioscience xxx xxx SØREN
BREGENHOLT has been appointed to strengthen Alligator Bioscience’s business development activities and clinical progress on an international level. Søren Bregenholt most reXXX xxx xxx cently served as Chief Executive Officer and Board Director at Macrophage Pharma in the UK. Previous experiences include Corporate Vice President positions at Novo Nordisk and Chief Operating Officer at the Danish biotech company Symphogen. He received his PhD from University of Copenhagen and did his post-doctoral training at Institute Pasteur in Paris. “I am really looking forward to the new challenge of leading Alligator Bioscience, a very dynamic and respected company in the exciting field of immunooncology. I am impressed by the robust quality of the clinical portfolio as well as the research and development capabilities that have brought the company to this stage,” says Bregenholt. 30 NORDICLIFESCIENCE.ORG CEO of Follicum xxx xxx KIM ARVID NIELSEN has experience in business development, investor relations and drug development from leading positions in both small and large pharmaceutical companies. Kim Arvid Nielsen is a physician and Executive Master of Business Administration with experience in business development, investor relations and drug development. Kim Arvid Nielsen has previously held a number of senior roles in smaller life science enterprises as well as global pharmaceutical companies, including Cytovac, Scandion Oncology, Serendex, Bayer, Pharmion, Ferrosan and Serono Nordic. “I see great medical and commercial potential in Follicum’s unique tissue repairing peptides and will do my utmost to contribute to the company’s continued value creation based on my previous experience in business and drug development,” says Nielsen. CEO of Betagenon xxx xxx JAMES HALL has joined the company as Chief Executive Officer. Hall brings senior healthcare and life science experience, including 12 years with AstraZeneca. While there, he held several commercial, R&D, and Business Development roles, including VP Global Marketing for the CV/GI Therapy Area, Global Product VP for Crestor, and VP Evaluation for the CV/Metabolism/Renal Therapy Area. Before that, James Hall was a member of the Pharmaceutical/Medical Products practice at McKinsey & Co. Hall has a BM, BCh in Clinical Medicine, and a D. Phil in Cell Physiology from Oxford University where he was a Rhodes Scholar. “I am incredibly excited to join Betagenon as we build on the scientific leadership of Thomas and the team, and drive to clinical proof of concept and show what direct activation of AMPK can deliver to patients,” says Hall. CARL-MAGNUS HÖGERKORP has experience from work within the field of immunology and autoimmune diseases, as well as international experience and previous management roles in the biotech sector. He holds a PhD in immunology from Lund University, as well as an MBA from Lund University School of Economics and Management. He has previously worked for Novo Nordisk and their initiatives within inflammation and autoimmune diseases. He also held leading positions in a number of different biotech companies in Lund, Sweden. As CSO at Xintela, he worked with regenerative medicine and oncology, and was part of the introduction of the company on Nasdaq First North. He was subsequently appointed CEO at start-up Edvince and most recently, he held the position of CEO at Canimguide Therapeutics. He has also been part of starting up ImModulate Pharma, where he was CEO during 2021. PHOTO BRIAN RENE EGEBJERG